文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗丙型肝炎病毒感染患者的疾病进展

Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-02-28

这项前瞻性多中心队列研究纳入拉丁美洲23家医院1760例接受直接抗病毒药物(DAA)治疗的丙型肝炎病毒感染者,中位随访26.2个月,总体疾病进展累积发生率为4.1%(95%CI 3.2%-5.1%)。

要点

  • DAA治疗丙肝后中位随访26.2个月,疾病进展累积发生率为4.1%。
  • 获得SVR降低肝失代偿风险(HR 0.3)和新发HCC风险(HR 0.2)。
  • 晚期肝纤维化、临床显著门脉高压和白蛋白低于3.5 mg/dL与疾病进展相关。

核心结论

  • DAA治疗丙型肝炎病毒感染显著降低新发肝脏相关并发症风险,应提供给所有患者而不论疾病分期。

研究设计与样本

  • 排除有肝失代偿史、肝细胞癌(HCC)史或实体器官移植史的患者。
  • 主要结局为DAA治疗开始后新发肝失代偿、HCC、肝移植或死亡,采用时间依赖Cox比例风险模型分析相关变量。

主要发现

  • 中位随访26.2个月(四分位距15.3-37.5个月),总体疾病进展累积发生率为4.1%(95%CI 3.2%-5.1%),SVR评估后为3.6%(95%CI 2.7%-4.7%)。
  • 与疾病进展相关的基线变量包括晚期肝纤维化(HR 3.4,95%CI 1.2-9.6)、临床显著门脉高压(HR 2.1,95%CI 1.2-3.8)和白蛋白水平低于3.5 mg/dL(HR 4.1,95%CI 2.3-7.6),分析时校正SVR作为时间协变量。

临床怎么用

  • 应给所有丙型肝炎病毒感染者提供DAA治疗,不论疾病分期。
  • 对晚期肝纤维化、临床显著门脉高压或白蛋白低于3.5 mg/dL的患者,治疗后仍需关注疾病进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new liver-related events. We aimed to evaluate the incidence of disease progression in patients treated with DAAs. METHODS: We performed a prospective multicenter cohort study of 1760 patients who received DAA treatment at 23 hospitals in Latin America, from May 1, 2016, through November 21, 2019. We excluded patients with a history of liver decompensation, hepatocellular carcinoma (HCC), or solid-organ transplantation. Disease progression after initiation of DAA therapy included any of the following new events: liver decompensation, HCC, liver transplantation, or death. Evaluation of variables associated with the primary outcome was conducted using a time-dependent Cox proportional hazards models. RESULTS: During a median follow-up period of 26.2 months (interquartile range, 15.3-37.5 mo), the overall cumulative incidence of disease progression was 4.1% (95% CI, 3.2%-5.1%), and after SVR assessment was 3.6% (95% CI, 2.7%-4.7%). Baseline variables associated with disease progression were advanced liver fibrosis (hazard ratio [HR], 3.4; 95% CI, 1.2-9.6), clinically significant portal hypertension (HR, 2.1; 95% CI, 1.2-3.8), and level of albumin less than 3.5 mg/dL (HR, 4.1; 95% CI, 2.3-7.6), adjusted for SVR achievement as a time covariable. Attaining an SVR reduced the risk of liver decompensation (HR, 0.3; 95% CI, 0.1-0.8; P = .016) and de novo HCC (HR, 0.2; 95% CI, 0.1%-0.8%; P = .02) in the overall cohort. CONCLUSIONS: Treatment of hepatitis C virus infection with DAAs significantly reduces the risk of new liver-related complications and should be offered to all patients, regardless of disease stage. Clinicaltrials.gov: NCT03775798.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Mendizabal M, Piñero F, Ridruejo E, et al. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. Clin Gastroenterol Hepatol. 2020. PMID: 32113892. doi:10.1016/j.cgh.2020.02.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。